Hypothesis

Age‑associated shifts in the gut microbiome increase luminal butyrate concentrations that inhibit host histone deacetylases, leading to elevated H3K9Ac and H3K18Ac at the CDKN2A/B promoter. This epigenetic drift drives p16INK4a up‑regulation in peripheral tissues and the brain, amplifying systemic inflammaging independent of cellular senescence triggers.

Mechanistic Rationale

Butyrate is a potent HDAC inhibitor that can raise acetyl marks on histones H3K9 and H3K18, the same modifications shown to activate CDKN2A transcription during senescence【https://pmc.ncbi.nlm.nih.gov/articles/PMC9551412/】. In young cells, Polycomb‑mediated H3K27me3 keeps the locus silent, a state reversed by JMJD3 demethylase under oncogenic stress【https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00405/full】. Chronic butyrate exposure could mimic this stress signal by lowering HDAC activity, thereby shifting the chromatin equilibrium toward acetylation even without DNA damage or oncogene activation.

Microbiome‑derived metabolites also reach the brain via the vagus nerve and circulation, where they may influence microglial CDKN2A expression through the same HDAC‑sensitive route. Caloric restriction, which lowers circulating butyrate, represses Ets‑1‑driven p16 activation【https://www.science.org/doi/10.1126/sageke.2004.44.pe40】, supporting the idea that metabolite levels tune this pathway.

Thus, an aging microbiome that overproduces butyrate acts as a chronic, low‑grade HDAC inhibitor, remodeling the epigenome of multiple organs and feeding the inflammatory loop characteristic of inflammaging.

Testable Predictions

1. Germ‑free mice colonized with butyrate‑high microbiomes will show increased H3K9Ac/H3K18Ac at the CDKN2A/B promoter in liver, adipose, and hippocampus compared with germ‑free mice colonized with butyrate‑low consortia.
2. Elevated p16INK4a mRNA and protein will correlate with butyrate levels in these tissues and with higher circulating IL‑6, TNF‑α, and CRP.
3. Pharmacological HDAC inhibition (e.g., with trichostatin A) in germ‑free mice receiving butyrate‑low microbiota will recapitulate the CDKN2A activation seen with butyrate‑high colonization.
4. Conversely, neutralizing butyrate with antibodies or feeding a high‑fiber, low‑butyrate diet will reduce CDKN2A acetylation and inflammaging markers in conventionally aged mice.

Experimental Approach

• Microbiome transplant: Transfer fecal matter from aged (24‑mo) vs. young (3‑mo) donor mice into germ‑free recipients; quantify luminal butyrate by GC‑MS.
• Chromatin profiling: Perform ChIP‑qPCR for H3K9Ac and H3K18Ac at the CDKN2A promoter in harvested tissues.
• Senescence readouts: Measure p16INK4a, SA‑β‑gal, and SASP cytokines.
• Intervention arms: (a) HDAC inhibitor treatment, (b) butyrate scavenger, (c) caloric restriction control.
• Statistical test: Two‑way ANOVA with factors microbiome source and treatment; falsifiability hinges on absence of acetylation or p16 changes despite high butyrate exposure.

If butyrate‑driven HDAC inhibition fails to alter CDKN2A chromatin state or inflammaging, the hypothesis is refuted; confirmation would establish a direct microbial‑epigenetic axis linking gut ecology to host aging.